Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05363670
PHASE2

Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

Sponsor: ARS Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.

Official title: A Phase 2, Single-Dose, Randomized, Active and Placebo Controlled, Four-Period, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 or Albuterol in Subjects With Persistent Asthma

Key Details

Gender

All

Age Range

12 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2022-07-28

Completion Date

2024-02-02

Last Updated

2026-07-14

Healthy Volunteers

No

Conditions

Interventions

DRUG

ARS-1 1 mg

ARS-1 1 mg

DRUG

Albuterol MDI

180 mcg

DRUG

Placebo

Placebo

DRUG

ARS-1 2mg

ARS-1 2mg

Locations (4)

University of South Florida

Tampa, Florida, United States

Institute for Asthma and Allergy

Chevy Chase, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Bernstein Clinical Research Center, LLC

Cincinnati, Ohio, United States